All 1 tracked stories fall under one category: market-trends. Agamree is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Root
All 1 tracked stories fall under one category: market-trends. Agamree is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. We currently track 1 Healthcare story that mention Root, all published on February 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Root. Shared-story counts are live from our verified record — not editorial picks.
Root and Catalyst Pharmaceuticals are scheduled to release their quarterly financial results this Wednesday, providing critical data points for the insurtech and orphan drug sectors. Investors are looking for Root's progress toward profitability and Catalyst's continued dominance in the LEMS market.